menu
    • menu
    [{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Rheumatology","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ISPM21","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"TAIWAN","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Rheumatology","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Taiwan Liposome Company \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Endo International"}]

    Find Clinical Drug Pipeline Developments & Deals by Taiwan Liposome Company

    Menu

    Taiwan Liposome Company

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Endo International

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthrit...

                            Details : Under the terms of the agreement, TLC will primarily be responsible for the development of the product TLC599 (Dexamethasone Sodium Phosphate) and EVL will primarily be responsible for obtaining regulatory approval and commercialization of the product in...

                            Brand Name : TLC599

                            Molecule Type : Small molecule

                            Upfront Cash : $30.0 million

                            June 13, 2022

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Endo International

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISPM21

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Dr...

                            Details : GS-441524 (named ISPM21) is main plasma metabolite of the antiviral prodrug remdesivir. Studies on inhalable liposomal ISPM21 showed significantly higher concentrations in the lungs than their conventional counterparts.

                            Brand Name : GS-441524

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 23, 2021

                            Lead Product(s) : ISPM21

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain

                            Details : TLC599 is a non-opioid, proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.

                            Brand Name : TLC599

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 28, 2020

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)

                            Details : In preclinical studies, TLC19 demonstrated 30-fold exposure in the lungs while achieving lower blood and heart exposure than oral HCQ and unformulated HCQ.

                            Brand Name : TLC19

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2020

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Taiwan Liposome Company

                            Taiwan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hy...

                            Details : The Phase I randomized, vehicle-controlled, blinded study will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.

                            Brand Name : TLC19

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2020

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth